Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy

References

• JepsenPOttPAndersenPKSorensenHTVilstrupHClinical course of alcoholic liver cirrhosis: a Danish population-based cohort studyHepatology20105151675168220186844
   PubMed Web of Science ®Google Scholar
• LeevyCBPhillipsJAHospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathyDig Dis Sci200752373774117245628
   PubMed Web of Science ®Google Scholar
• PoordadFFReview article: the burden of hepatic encephalopathyAliment Pharmacol Ther200725Suppl 13917295846
   PubMed Web of Science ®Google Scholar
• FerenciPLockwoodAMullenKTarterRWeissenbornKBleiATHepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998Hepatology200235371672111870389
   PubMed Web of Science ®Google Scholar
• CordobaJNew assessment of hepatic encephalopathyJ Hepatol20115451030104021145874
   PubMed Web of Science ®Google Scholar
• BajajJSCordobaJMullenKDReview article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statementAliment Pharmacol Ther201133773974721306407
   PubMed Web of Science ®Google Scholar
• MardiniHRecordCPathogenesis of hepatic encephalopathy: lessons from nitrogen challenges in manMetab Brain Dis201328220120723180318
   PubMed Web of Science ®Google Scholar
• BajajJSReview article: the modern management of hepatic encephalopathyAliment Pharmacol Ther201031553754720002027
   PubMed Web of Science ®Google Scholar
• PrakashRMullenKDMechanisms, diagnosis and management of hepatic encephalopathyNat Rev Gastroenterol Hepatol20107951552520703237
   PubMed Web of Science ®Google Scholar
• RiordanSMWilliamsRGut flora and hepatic encephalopathy in patients with cirrhosisN Engl J Med2010362121140114220335591
   PubMed Web of Science ®Google Scholar
• PhongsamranPVKimJWCupo AbbottJRosenblattAPharmacotherapy for hepatic encephalopathyDrugs20107091131114820518580
   PubMed Web of Science ®Google Scholar
• ScarpignatoCPelosiniIRifaximin, a poorly absorbed antibiotic: pharmacology and clinical potentialChemotherapy200551Suppl 1366615855748
   PubMed Web of Science ®Google Scholar
• BajajJSHeumanDMSanyalAJModulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathyPloS One201384e6004223565181
   PubMed Web of Science ®Google Scholar
• BajajJSHeumanDMWadeJBRifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathyGastroenterology20111402478487. e47120849805
   PubMed Web of Science ®Google Scholar
• BassNMMullenKDSanyalARifaximin treatment in hepatic encephalopathyN Engl J Med2010362121071108120335583
   PubMed Web of Science ®Google Scholar
• BucciLPalmieriGCDouble-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathyCurr Med Res Opin19931321091188325041
   PubMed Web of Science ®Google Scholar
• De MarcoFSantamaria AmatoPD’ArienzoARifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary reportCurr Ther Res1984364668674
   Web of Science ®Google Scholar
• MasARodesJSunyerLComparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trialJ Hepatol2003381515812480560
   PubMed Web of Science ®Google Scholar
• PariniPCARonchiMSalzettaAMazellaGRodaEEffect of rifaximin and paromycin in the treatment of portal-systemic encephalopathyCurr Ther Res19925213439
   Web of Science ®Google Scholar
• PharmacyChecker [homepage on the Internet] Available from: http://www.pharmacychecker.com/compare-drug-prices-online-pharmacies/rifaximin-550+mg/79995/197553/Accessed February 1, 2014
   Google Scholar
• NeffGPharmacoeconomics of hepatic encephalopathyPharmacotherapy2010305 Pt 228S32S20412038
   PubMed Web of Science ®Google Scholar
• Di PiazzaSGabriella FilippazzoMValenzaLMRifaximine versus neomycin in the treatment of portosystemic encephalopathyItal J Gastroenterol19912374034071742538
   PubMedGoogle Scholar
• EftimiadiCDeleoCSchitoGCTreatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycinDrugs Exp Clin Res198410691696
   Google Scholar
• RiggioOMasiniAEfratiCPharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled studyJ Hepatol200542567467915826716
   PubMed Web of Science ®Google Scholar
• SongKH LKKimMHPaikYHThe clinical efficacy of rifaximin in the treatment of hepatic encephalopathy (comparison with lactulose)Hepatology2000324407A
   Web of Science ®Google Scholar
• TestaREftimiadiCSukkarGSA non-absorbable rifamycin for treatment of hepatic encephalopathyDrugs Exp Clin Res19851163873923836135
   PubMedGoogle Scholar
• VenturiniIFerrieriAFarinaFEvaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot studyDrugs Exp Clin Res200531416116816223206
   PubMedGoogle Scholar
• WilliamsRJamesOFWarnesTWMorganMYEvaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre studyEur J Gastroenterol Hepatol200012220320810741936
   PubMed Web of Science ®Google Scholar
• BassNMAhmedAJohnsonLGardnerJDRifaximin treatment is beneficial for mild hepatic encephalopathyHepatology200440646A (abstract)15349903
   PubMed Web of Science ®Google Scholar
• FeraGFANigroMSchiraldiOFerrieriARifaximin in the treatment of hepatic encephalopathyEur J Clin Res199345766
   Google Scholar
• FestiDMazzellaGOrsiniMRifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safetyCurr Ther Res1993545598609
   Web of Science ®Google Scholar
• LoguercioCFedericoADe GirolamoVFerrieriADel Vecchio BlancoCCyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical studyMinerva Gastroenterol Dietol2003491536216481971
   PubMedGoogle Scholar
• MassaPVFDoderoMTreatment of hepatic encephalopathy with rifaximinEur J Clin Res19934718
   Google Scholar
• MiglioFValpianiDRosselliniSRFerrieriARifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trialCurr Med Res Opin199713105936019327194
   PubMed Web of Science ®Google Scholar
• PaikYHLeeKSHanKHComparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized studyYonsei Med J200546339940715988813
   PubMed Web of Science ®Google Scholar
• PedrettiGCalzettiCMissaleGFiaccadoriFRifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trialItal J Gastroenterol19912341751781751811
   PubMedGoogle Scholar
• SharmaBCSharmaPLuniaMKSrivastavaSGoyalRSarinSKA randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathyAm J Gastroenterol201310891458146323877348
   PubMed Web of Science ®Google Scholar
• SidhuSSGoyalOMishraBPSoodAChhinaRSSoniRKRifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial)Am J Gastroenterol2011106230731621157444
   PubMed Web of Science ®Google Scholar
• SanyalAYounossiZMBassNMRandomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled studyAliment Pharmacol Ther201134885386121848797
   PubMed Web of Science ®Google Scholar
• IrimaRTrifanAEfficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hospitalizations in cirrhosisRev Med Chir Soc Med Nat Iasi201211641021102723700882
   PubMedGoogle Scholar
• TandonPDelisleATopalJEGarcia-TsaoGHigh prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver centerClin Gastroenterol Hepatol201210111291129822902776
   PubMed Web of Science ®Google Scholar
• VlachogiannakosJViazisNVasianopoulouPVafiadisIKaramanolisDGLadasSDLong-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosisJ Gastroenterol Hepatol201328345045523216382
   PubMed Web of Science ®Google Scholar
• BajajJBEPatersonCForbesWPLong-term use of rifaximin is associated with reduced hospitalizations, prolonged remission: a placebo crossover analysisHepatology201256Suppl 4925A926A
   Google Scholar
• O’LearyJGReddyKRWongFLong-term antibiotic and proton-pump inhibitor use are strong predictors of recurrent infections in cirrhosis: a prospective multi-center study from NACSELDJ Hepatol201358Suppl 1S97
   Web of Science ®Google Scholar
• SanyalAMKBassNMFrederickTRates of commonly occurring infections in cirrhosis patients remain stable during long-term rifaximin treatmentJ Hepatol201256Suppl 1S255S256
   Web of Science ®Google Scholar
• MantryPSMunsafSRifaximin for the treatment of hepatic encephalopathyTransplant Proc201042104543454721168733
   PubMed Web of Science ®Google Scholar
• NeffGWJonesMBrodaTDurability of rifaximin response in hepatic encephalopathyJ Clin Gastroenterol201246216817122011586
   PubMed Web of Science ®Google Scholar
• NeffGWJonesMJonasMLack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysisJ Clin Gastroenterol201347218819223314671
   PubMed Web of Science ®Google Scholar
• NeffGWKemmerNZachariasVCAnalysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathyTransplant Proc200638103552355517175328
   PubMed Web of Science ®Google Scholar
• NeffGWAssessing treatment patterns in patients with overt hepatic encephalopathyHepatology201256Suppl 4945A
   Google Scholar
• BajajJSPinkertonSDSanyalAJHeumanDMDiagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysisHepatology20125541164117122135042
   PubMed Web of Science ®Google Scholar
• HuangEEsrailianESpiegelBMThe cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy – a decision analysisAliment Pharmacol Ther20072681147116117894657
   PubMed Web of Science ®Google Scholar
• NeffGWKemmerNDuncanCAlsinaAUpdate on the management of cirrhosis – focus on cost-effective preventative strategiesClinicoecon Outcomes Res2013514315223626470
   PubMedGoogle Scholar
• SharmaBCSharmaPAgrawalASarinSKSecondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placeboGastroenterology20091373885891891. e119501587
   PubMed Web of Science ®Google Scholar
• BajajJSSanyalAJBellDGillesHHeumanDMPredictors of the recurrence of hepatic encephalopathy in lactulose-treated patientsAliment Pharmacol Ther20103191012101720136802
   PubMed Web of Science ®Google Scholar
• NeffGFactors affecting compliance and persistence with treatment for hepatic encephalopathyPharmacotherapy2010305 Pt 222S27S20412037
   PubMed Web of Science ®Google Scholar
• Chemistdirect.co.uk [homepage on the Internet]Lactulose solutionOldbury, UKChemist Direct Available from: http://www.chemistdirect.co.uk/lactulose-solution_1_10158.html#10158Accessed January 9, 2014
   Google Scholar
• Drugs.com [homepage on the Internet]Xifaxan Available from: http://www.drugs.com/xifaxan.htmlAccessed January 9, 2014
   Google Scholar
• PrakashRKKannaSMullenKDEvolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosisClin Ther20133591458147323972578
   PubMed Web of Science ®Google Scholar
• GluudLLDamGBorreMLactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?Metab Brain Dis201328222122523275147
   PubMed Web of Science ®Google Scholar